Amplify Weight Loss Drug & Treatment ETF
ETFYour view on THNR
Amplify Weight Loss Drug & Treatment ETF
ETFAmplifySentiment
AUM (USD)
$5.81M
Expense Ratio
0.59%
Holdings
20
Sentiment
Overview for Amplify Weight Loss Drug & Treatment ETF
- Fund Type
- ETF
- Fund Issuer
- Amplify
- Asset Class
- Equity
- Sector
- Financial Services
- Industry
- Asset Management
- Inception Date
- May 21, 2024
- Domicile
- US
- Website
- amplifyetfs.com/thnr
- Fund Type
- ETF
- Fund Issuer
- Amplify
- Asset Class
- Equity
- Sector
- Financial Services
- Industry
- Asset Management
- Inception Date
- May 21, 2024
- Domicile
- US
- Website
- amplifyetfs.com/thnr
- Fund Type
- ETF
- Fund Issuer
- Amplify
- Asset Class
- Equity
- Sector
- Financial Services
- Industry
- Asset Management
- Inception Date
- May 21, 2024
- Domicile
- US
- Website
- amplifyetfs.com/thnr
About this fund
THNR provides access to global companies expected to economically benefit from weight loss drug development. THNR seeks investment results that generally correspond to the performance (before fees and expenses) of the VettaFi Weight Loss Drug & Treatment Index.
THNR Stock Price
Key Facts
EquityExpense Ratio
0.59%
AUM
$5.81M
Fund Details
Expense Ratio
0.59%
Assets Under Management
$5.81M
NAV
$25.25 USD
Holdings
20
Average Volume
1.9K
Inception Date
May 21, 2024
Asset Class
Equity
Fund Issuer
Amplify
Domicile
US
ISIN
US0321085328
CUSIP
032108532
NAV Currency
USD
Expense Ratio
0.59%
Assets Under Management
$5.81M
NAV
$25.25 USD
Holdings
20
Average Volume
1.9K
Inception Date
May 21, 2024
Asset Class
Equity
Fund Issuer
Amplify
Domicile
US
ISIN
US0321085328
CUSIP
032108532
NAV Currency
USD
Latest headlines and company announcements for this company. Press releases and market coverage, newest first.
News
this company valued side by side against its closest peers. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.